Any feedback?
Literature summary extracted from
- New chemiluminescent substrates of paraoxonase 1 with improved specificity synthesis and properties (2015), Appl. Biochem. Biotechnol., 176, 301-316 .
Activating Compound
| EC Number | Activating Compound | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.1.1.2 | NaCl | - |
Homo sapiens |  |
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.1.8.1 | diagnostics | decrease of serum PON1 activities is usually related to many chronic diseases, such as atherosclerosis, diabetes, cancers, migraine, pulmonary tuberculosis, polycystic ovary syndrome, gastroesophageal malignancies, depression, nephritic syndrome, hemodialysis, metabolic syndrome, and liver disease. Determination of PON1 activity has a significant diagnostic value in predicting disease status. PON1 shows very good adaptability in assay development with different substrates, PON1 substrate exhibit many degrees of freedom in docking simulations | Homo sapiens |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.1.1.2 | EDTA | - |
Homo sapiens | |
| 3.1.1.2 | NaCl | 1.0 mM NaCl decreases the serum arylesterase activity of the enzyme | Homo sapiens | |
| 3.1.8.1 | EDTA | EDTA inhibits both the Ca2+-PON1-mediated hydrolysis and the Ca2+-serum-mediated hydrolysis of acridinium esters | Homo sapiens | |
KM Value [mM]
| EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|---|
| 3.1.8.1 | additional information | - |
additional information | rhPON1-mediated hydrolyses of the acridinium esters obey first-order reaction kinetics, kinetic analysis of serum-catalyzed and recombinant enzyme-catalyzed hydrolysis of acridinium esters, detailed overview | Homo sapiens |
Metals/Ions
| EC Number | Metals/Ions | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.1.8.1 | Ca2+ | dependent on | Homo sapiens | |
| 3.1.8.1 | NaCl | activation effects of NaCl on PON1 activity and serum arylesterase activity, kinetics, overview | Homo sapiens | |
Natural Substrates/ Products (Substrates)
| EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.1.8.1 | diethyl-paraoxon + H2O | Homo sapiens | - |
diethyl phosphate + 4-nitrophenol | - |
? | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.1.1.2 | Homo sapiens | - |
- |
- |
| 3.1.8.1 | Homo sapiens | P27169 | - |
- |
Source Tissue
| EC Number | Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|---|
| 3.1.1.2 | blood serum | - |
Homo sapiens | - |
| 3.1.8.1 | commercial preparation | purified recombinant human PON1 | Homo sapiens | - |
| 3.1.8.1 | serum | - |
Homo sapiens | - |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.1.1.2 | 4-nitrophenyl acetate + H2O | - |
Homo sapiens | 4-nitrophenol + acetate | - |
? | |
| 3.1.1.2 | 9-(2,4-dimethylphenoxycarbonyl)-10-methylacridinium triflate + H2O | - |
Homo sapiens | 2,4-dimethylphenol + 10-methylacridinium trifluoromethanesulfonate | - |
? | |
| 3.1.1.2 | 9-(4-chlorophenoxycarbonyl)-10-methylacridinium triflate + H2O | - |
Homo sapiens | 4-chlorophenol + 10-methylacridinium trifluoromethanesulfonate | - |
? | |
| 3.1.1.2 | 9-(4-methylphenoxycarbonyl)-10-methylacridinium triflate + H2O | - |
Homo sapiens | 4-methylphenol + 10-methylacridinium trifluoromethanesulfonate | - |
? | |
| 3.1.1.2 | 9-(4-tert-butylphenoxycarbonyl)-10-methylacridinium triflate + H2O | - |
Homo sapiens | 4-tert-butylphenol + 10-methylacridinium trifluoromethanesulfonate | - |
? | |
| 3.1.1.2 | 9-(phenyloxycarbonyl)-10-methylacridinium triflate + H2O | - |
Homo sapiens | phenol + 10-methylacridinium trifluoromethanesulfonate | - |
? | |
| 3.1.8.1 | 9-(2,4-dimethylphenoxycarbonyl)-10-methylacridinium triflate + H2O | synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | 9-(4-chlorophenoxycarbonyl)-10-methylacridinium triflate + H2O | synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | 9-(4-methylphenoxycarbonyl)-10-methylacridinium triflate + H2O | synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | 9-(4-tert-butylphenoxycarbonyl)-10-methylacridinium triflate + H2O | synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | 9-(phenyloxycarbonyl)-10-methylacridinium triflate + H2O | synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | diethyl-paraoxon + H2O | - |
Homo sapiens | diethyl phosphate + 4-nitrophenol | - |
? | |
| 3.1.8.1 | additional information | PON1 shows very good adaptability in assay development with different substrates, PON1 substrate exhibit many degrees of freedom in docking simulations. The relative chemiluminescent efficiency for the five acridinium esters ranks as the following descreasing order: unsubstituted, 2,4-dimethylphenoxy-, 4-methylphenoxy-, 4-tertbutylphenoxy-, and chloro-acridinium ester. Selfhydrolysis of the five acridinium esters in Tris-HCl buffer, at pH 7.5 and 25°C is insignificant during 22 min, but between 1.03% and 27.17% after 12 weeks | Homo sapiens | ? | - |
? | |
| 3.1.8.1 | phenyl acetate + H2O | arylesterase activity | Homo sapiens | phenol + acetate | - |
? | |
Subunits
| EC Number | Subunits | Comment | Organism |
|---|---|---|---|
| 3.1.8.1 | More | paraoxonase 1 is a Ca2+-dependent hydrolase with three carbohydrate chains | Homo sapiens |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.1.8.1 | paraoxonase 1 | - |
Homo sapiens |
| 3.1.8.1 | PON1 | - |
Homo sapiens |
Temperature Optimum [°C]
| EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|---|
| 3.1.8.1 | 25 | - |
assay at | Homo sapiens |
pH Optimum
| EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|---|
| 3.1.8.1 | 7.5 | 8 | assay at | Homo sapiens |
General Information
| EC Number | General Information | Comment | Organism |
|---|---|---|---|
| 3.1.8.1 | malfunction | decrease of serum PON1 activities is usually related to many chronic diseases, such as atherosclerosis, diabetes, cancers, migraine, pulmonary tuberculosis, polycystic ovary syndrome, gastroesophageal malignancies, depression, nephritic syndrome, hemodialysis, metabolic syndrome, and liver disease. Determination of PON1 activity has a significant diagnostic value in predicting disease status | Homo sapiens |
| 3.1.8.1 | physiological function | paraoxonase 1 (PON1) is an physiologically important hydrolase. The enzyme activity decreases in patients with liver disease, diabetes, coronary heart disease, etc. Recombinant human PON1 shows selectivity over other serum esterases such as lipase, acetylcholinesterase, and esterase D more than 300folds. PON1 can prevent lipid oxidation in low-density lipoprotein and thus decrease the levels of oxidized lipids that are associated with aging, anoxia-reoxygenation injury, and atherosclerosis. Additionally, some evidences demonstrates its key role in metabolism of drugs | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
